MEDICINE 2019 10.1097/MD.0000000000017641
Changing trends in lymphoid neoplasm distribution in South Korea: analysis of 8615 cases from a single institute, 1997-2016 An observational study
Sim1, J; Takayama, T; Cho, J; Kim, SJ; Kim, WS; Ree, HJ; Ko, YH

BMC CANCER 2019 10.1186/s12885-019-6303-z
Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma
Kim1, SJ; Yoon, DH; Kang, HJ; Hong, JY; Lee, HS; Oh, SY; Shin, HJ; Kong, JH; Yi, JH; Sakamoto, K; Ko, YH; Huh, J; Lee, SS; Takeuchi, K; Shin, DY; Suh, C; Kim, WS

ANN HEMATOL 2019 10.1007/s00277-019-03791-y
Multicenter retrospective analysis of the clinicopathologic features of monomorphic epitheliotropic intestinal T-cell lymphoma
Yi1, JH; Lee, GW; Do, YR; Jung, HR; Hong, JY; Yoon, DH; Suh, C; Choi, YS; Yi, SY; Sohn, BS; Kim, BS; Oh, SY; Park, J; Jo, JC; Lee, SS; Oh, YH; Kim, SJ; Kim, WS

AM J HEMATOL 2019 10.1002/ajh.25674
Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas
Foss1, FM; Horwitz, SM; Civallero, M; Bellei, M; Marcheselli, L; Kim, WS; Cabrera, ME; Dlouhy, I; Nagler, A; Advani, RH; Pesce, EA; Ko, YH; Montoto, S; Chiattone, C; Moskowitz, A; Spina, M; Cesaretti, M; Biasoli, I; Federico, M

SCI REP-UK 2019 10.1038/s41598-019-51522-0
A clinicohaematological prognostic model for nasal-type natural killer/T-cell lymphoma: A multicenter study
Tan1, KM; Chia, B; Lim, JQ; Khoo, LP; Cheng, CL; Tan, L; Poon, E; Somasundaram, N; Farid, M; Tang, TPL; Tao, M; Cheah, DMZ; Laurensia, Y; Pang, JWL; Song, T; Tan, J; Huang, DC; Kim, SJ; Kim, WS; Ong, CK; Lim, ST; Chan, JY

CANCER RES TREAT 2019 10.4143/crt.2018.555
Body Cavity- Based Lymphoma in a Country with Low Human Immunodeficiency Virus Prevalence: A Series of 17 Cases from the Consortium for Improving Survival of Lymphoma
Shin1, J; Ko, YH; Oh, SY; Yoon, DH; Lee, JO; Kim, JS; Park, Y; Shin, HJ; Kim, SJ; Won, JH; Yoon, SS; Kim, WS; Koh, Y

BMC CANCER 2019 10.1186/s12885-019-6057-7
Interleukin-6 mediates resistance to PI3K-pathway-targeted therapy in lymphoma
Kim1, JH; Kim, WS; Park, C

INT J HEMATOL 2019 10.1007/s12185-019-02693-z
The Glasgow Prognostic Score is a significant predictor of peripheral T-cell lymphoma (PTCL) treated with CHOP-based chemotherapy and comparable with PTCL prognostic scores
Huh1, S; Oh, SY; Lee, S; Lee, JH; Kim, SH; Lee, GW; Kim, SJ; Kim, WS; Lee, HS; Jo, JC; Kim, MJ; Kwon, JH; Kim, HJ

CANCER COMMUN 2019 10.1186/s40880-019-0403-7
Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study
Oh1, SY; Kim, WS; Kim, JS; Kim, SJ; Yoon, DH; Yang, DH; Lee, WS; Kim, HJ; Yhim, HY; Jeong, SH; Won, JH; Lee, S; Kong, JH; Lim, SN; Ji, JH; Kwon, KA; Lee, GW; Lee, JH; Lee, HS; Shin, HJ; Suh, C

LEUKEMIA LYMPHOMA 2019 10.1080/10428194.2019.1573998
Analysis of circulating tumor DNA by targeted ultra-deep sequencing across various non-Hodgkin lymphoma subtypes
Shin1, SH; Kim, YJ; Lee, D; Cho, D; Ko, YH; Cho, J; Park, WY; Park, D; Kim, SJ; Kim, WS

LEUKEMIA LYMPHOMA 2019 10.1080/10428194.2019.1622100
A phase II trial of bendamustine, carboplatin, and dexamethasone for refractory or relapsed peripheral T-cell lymphoma (BENCART trial)
Park1, BB; Kim, WS; Suh, C; Hong, JY; Yang, DH; Lee, WS; Do, YR; Koh, YI; Won, JH; Kim, MK; Jo, JC; Hyun, SY; Kim, JA; Oh, YH; Lee, SS

CANCER RES TREAT 2019 10.4143/crt.2018.190
Radiation Therapy Outcome and Clinical Features of Duodenal-Type Follicular Lymphoma
Lee1, H; Oh, D; Yang, K; Ko, YH; Ahn, YC; Kim, WS; Kim, SJ

CANCER RES TREAT 2019 10.4143/crt.2018.191
Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus-Positive and -Negative Relapsed or Refractory Non-Hodgkin Lymphomas
Kim1, SJ; Hyeon, J; Cho, I; Ko, YH; Kim, WS

CLIN LYMPHOMA MYELOMA LEUK 2019 10.1016/j.clml.2018.11.003
Multicenter Phase 2 Study of Reduced-Dose CHOP Chemotherapy Combined With Rituximab for Elderly Patients With Diffuse Large B-Cell Lymphoma
Park1, S; Jo, JC; Do, YR; Yang, DH; Lim, SN; Lee, WS; Kim, WS; Lee, HS; Hong, DS; Kim, HJ; Shin, HJ

J CLIN ONCOL 2019 10.1200/JCO.18.00899
Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
O'Connor1, OA; Ozcan, M; Jacobsen, ED; Roncero, JM; Trotman, J; Demeter, J; Masszi, T; Pereira, J; Ramchandren, R; Beaven, A; Caballero, D; Horwitz, SM; Lennard, A; Turgut, M; Hamerschlak, N; d'Amore, FA; Foss, F; Kim, WS; Leonard, JP; Zinzani, PL; Chiattone, CS; Hsi, ED; Trumper, L; Liu, H; Sheldon-Waniga, E; Ullmann, CD; Venkatakrishnan, K; Leonard, EJ; Shustov, AR

ANN HEMATOL 2019 10.1007/s00277-018-3516-1
Validation of the Marginal Zone Lymphoma International Prognostic Index
Hong1, J; Cho, J; Ko, YH; Kim, SJ; Kim, WS

LEUKEMIA LYMPHOMA 2019 10.1080/10428194.2018.1480772
Serum IL18 is associated with hemophagocytosis and poor survival in extranodal natural killer/T-cell lymphoma
Lim1, SW; Ryu, KJ; Lee, H; Ko, YH; Kim, WS; Kim, SJ

CYTOKINE 2019 10.1016/j.cyto.2018.10.009
Profiles of serum cytokines and their clinical implications in patients with peripheral T-cell lymphoma
Yi1, JH; Ryu, KJ; Ko, YH; Kim, WS; Kim, SJ

BLOOD 2019 10.1182/blood-2018-04-848044
Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy
Kusumoto1, S; Arcaini, L; Hong, XN; Jin, J; Kim, WS; Kwong, YL; Peters, MG; Tanaka, Y; Zelenetz, AD; Kuriki, H; Fingerle-Rowson, G; Nielsen, T; Ueda, E; Piper-Lepoutre, H; Sellam, G; Tobinai, K

LANCET 2019 10.1016/S0140-6736(18)32984-2
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
Horwitz1, S; O'Connor, OA; Pro, B; Illidge, T; Fanale, M; Advani, R; Bartlett, NL; Christensen, JH; Morschhauser, F; Domingo-Domenech, E; Rossi, G; Kim, WS; Feldman, T; Lennard, A; Belada, D; Illes, A; Tobinai, K; Tsukasaki, K; Yeh, SP; Shustov, A; Huttmann, A; Savage, KJ; Yuen, S; Iyer, S; Zinzani, PL; Hua, ZW; Little, M; Rao, S; Woolery, J; Manley, T; Trumper, L; Aboulafia, D; Alpdogan, O; Ando, K; Arcaini, L; Baldini, L; Bellam, N; Bartlett, N; Ben Yehuda, D; Benedetti, F; Borchman, P; Bordessoule, D; Brice, P; Briones, J; Caballero, D; Carella, AM; Chang, H; Cheong, JW; Cho, SG; Choi, I; Choquet, S; Colita, A; Congui, AG; D'amore, F; Dang, N; Davison, K; De Guibert, S; Brown, PD; Delwail, V; Demeter, J; di Raimondo, F; Do, YR; Domingo, E; Douvas, M; Dreyling, M; Ernst, T; Fay, K; Ferrero, SF; Flinn, IW; Forero-Torres, A; Fox, C; Friedberg, J; Fukuhara, N; Garcia-Marco, J; Cruz, JG; Codina, JG; Gressin, R; Grigg, A; Gurion, R; Haioun, C; Hajek, R; Hanel, M; Hatake, K; Hensen, R; Horo

J HEMATOL ONCOL 2018 10.1186/s13045-018-0687-0
Treatment of localized extranodal NK/T cell lymphoma, nasal type: a systematic review
Kim1, SJ; Yoon, SE; Kim, WS

ANN HEMATOL 2018 10.1007/s00277-018-3442-2
The cell-of-origin classification of diffuse large B cell lymphoma in a Korean population by the Lymph2Cx assay and its correlation with immunohistochemical algorithms
Hwang1, HS; Yoon, DH; Hong, JY; Park, CS; Lee, YS; Ko, YH; Kim, SJ; Kim, WS; Suh, C; Huh, J

EUR J NUCL MED MOL I 2018 10.1007/s00259-018-4093-1
A risk stratification model for nodal peripheral T-cell lymphomas based on the NCCN-IPI and posttreatment Deauville score
Yhim1, HY; Park, Y; Han, YH; Kim, S; Kang, SR; Moon, JH; Jeong, JH; Shin, HJ; Kim, K; Choi, YS; Kim, K; Kim, MK; Kong, E; Kim, DS; Eo, JS; Lee, JH; Kang, DY; Lee, WS; Lee, SM; Do, YR; Ham, JS; Kim, SJ; Kim, WS; Choi, JY; Yang, DH; Kwak, JY

BIOL BLOOD MARROW TR 2018 10.1016/j.bbmt.2018.07.034
Allogeneic Stem Cell Transplantation for Patients with Natural Killer/T Cell Lymphoid Malignancy: A Multicenter Analysis Comparing Upfront and Salvage Transplantation
Jeong1, SH; Song, HN; Park, JS; Yang, DH; Koh, Y; Yoon, SS; Lee, HW; Eom, HS; Won, JH; Kim, WS; Kim, SJ

CANCER SCI 2018 10.1111/cas.13844
Vitamin D deficiency is associated with inferior survival of patients with extranodal natural killer/T-cell lymphoma
Kim1, SJ; Shu, C; Ryu, KJ; Kang, D; Cho, J; Ko, YH; Lee, SY; Guallar, E; Zhao, W; Kim, WS

Lancet Haematol 2018 10.1016/S2352-3026(18)30157-1
Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial
Ogura1, M; Sancho, JM; Cho, SG; Nakazawa, H; Suzumiya, J; Tumyan, G; Kim, JS; Lennard, A; Mariz, J; Ilyin, N; Jurczak, W; Martinez, AL; Samoilova, O; Zhavrid, E; Ruiz, EY; Trneny, M; Popplewell, L; Coiffier, B; Buske, C; Kim, WS; Lee, SJ; Lee, SY; Bae, YJ; Kwak, LW

ANN HEMATOL 2018 10.1007/s00277-018-3387-5
Treating synchronous bilateral ocular adnexal marginal zone lymphoma: the consortium for improving survival of lymphoma study
Oh1, SY; Kim, WS; Kang, HJ; Lee, JH; Huh, S; Kim, S; Yoon, DH; Hong, JY; Lee, WS; Kim, HJ; Won, JH; Park, BB; Lee, SI; Suh, C

INVEST NEW DRUG 2018 10.1007/s10637-018-0582-0
Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy
Cho1, H; Yoon, DH; Kim, KP; Bae, KS; Kim, WS; Eom, HS; Kim, JS; Hong, JY; Kim, SJ; Lee, H; Kim, SJ; Suh, C

CANCER RES TREAT 2018 10.4143/crt.2017.207
Health-Related Quality of Life in Non-Hodgkin Lymphoma Survivors: A Prospective Cohort Study
Kang1, D; Cho, J; Kim, IR; Kim, MK; Kim, WS; Kim, SJ

MODERN PATHOL 2018 10.1038/s41379-018-0064-0
Targeted deep sequencing of gastric marginal zone lymphoma identified alterations of TRAF3 and TNFAIP3 that were mutually exclusive for MALT1 rearrangement
Hyeon1, J; Lee, B; Shin, SH; Yoo, HY; Kim, SJ; Kim, WS; Park, WY; Ko, YH

ANN HEMATOL 2018 10.1007/s00277-018-3313-x
Significance of circulating Epstein-Barr virus DNA monitoring after remission in patients with extranodal natural killer T cell lymphoma
Cho1, J; Kim, SJ; Park, S; Yoo, KH; Ki, CS; Ko, Y; Kim, WS

BONE MARROW TRANSPL 2018 10.1038/s41409-018-0097-5
Satisfaction with sexual activity and sexual dysfunction in hematopoietic stem cell transplantation survivors and their partners: a couple study
Yoo1, KH; Kang, D; Kim, IR; Choi, EK; Kim, JS; Yoon, SS; Lee, CH; Park, S; Kim, SJ; Kim, K; Kim, WS; Jung, CW; Choi, HJ; Jang, JH; Cho, J

ANN HEMATOL 2018 10.1007/s00277-018-3317-6
Bendamustine plus rituximab for relapsed or refractory diffuse large B cell lymphoma: a multicenter retrospective analysis
Hong1, JY; Yoon, DH; Suh, C; Kim, WS; Kim, SJ; Jo, JC; Kim, JS; Lee, WS; Oh, SY; Park, Y; Kim, SY; Lee, MH; Lee, HS; Do, YR

HAEMATOL-HEMATOL J 2018 10.3324/haematol.2017.186577
The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project
Bellei1, M; Foss, FM; Shustov, AR; Horwitz, SM; Marcheselli, L; Kim, WS; Cabrera, ME; Dlouhy, I; Nagler, A; Advani, RH; Pesce, EA; Ko, YH; Martinez, V; Montoto, S; Chiattone, C; Moskowitz, A; Spina, M; Biasoli, I; Manni, M; Federico, M

CANCER SCI 2018 10.1111/cas.13597
Early disease progression in patients with localized natural killer/T-cell lymphoma treated with concurrent chemoradiotherapy
Yamaguchi1, M; Suzuki, R; Kim, SJ; Ko, YH; Oguchi, M; Asano, N; Miyazaki, K; Terui, Y; Kubota, N; Maeda, T; Kobayashi, Y; Amaki, J; Soejima, T; Saito, B; Shimoda, E; Fukuhara, N; Tsukamoto, N; Shimada, K; Choi, I; Utsumi, T; Ejima, Y; Kim, WS; Katayama, N

BRIT J HAEMATOL 2018 10.1111/bjh.15258
Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network
Federico1, M; Bellei, M; Marcheselli, L; Schwartz, M; Manni, M; Tarantino, V; Pileri, S; Ko, YH; Cabrera, ME; Horwitz, S; Kim, WS; Shustov, A; Foss, FM; Nagler, A; Carson, K; Pinter-Brown, LC; Montoto, S; Spina, M; Feldman, TA; Lechowicz, MJ; Smith, SM; Lansigan, F; Gabus, R; Vose, JM; Advani, RH

CANCER RES TREAT 2018 10.4143/crt.2017.182
Low-Dose Radiation Therapy for Primary Conjunctival Marginal Zone B-Cell
Lee1, GI; Oh, D; Kim, WS; Kim, SJ; Ko, YH; Woo, KI; Kim, YD; Ahn, YC

Eur J Oncol Nurs 2018 10.1016/j.ejon.2018.01.012
Use of complementary and alternative medicine by lymphoma survivors in South Korea
Kim1, K; Kim, SH; Ok, ON; Kim, IR; Lee, S; Kim, SH; Kim, WS; Ryu, MH; Lee, MH

ANN ONCOL 2018 10.1093/annonc/mdx764
Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial
Witzig1, TE; Tobinai, K; Rigacci, L; Ikeda, T; Vanazzi, A; Hino, M; Shi, Y; Mayer, J; Costa, LJ; Silva, CDB; Zhu, J; Belada, D; Bouabdallah, K; Kattan, JG; Kuruvilla, J; Kim, WS; Larouche, JF; Ogura, M; Ozcan, M; Fayad, L; Wu, C; Fan, J; Louveau, AL; Voi, M; Cavalli, F

HUM PATHOL 2018 10.1016/j.humpath.2017.12.006
Identification of T-cell receptor expression in EBV-positive neoplastic cells in extranodal NK/T-cell lymphoma, nasal-type, and comparison with T-cell receptor gene rearrangement by BIOMED-2 assay
Takayama1, T; Shin, S; Kang, S; Kim, SJ; Kim, WS; Ko, YH

Blood Cancer J 2018 10.1038/s41408-018-0056-9
CXCR4 can induce PI3K delta inhibitor resistance in ABC DLBCL
Kim1, JH; Kim, WS; Ryu, KJ; Kim, SJ; Park, C

ANN ONCOL 2018 10.1093/annonc/mdx684
Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/IINK/T-cell lymphoma
Kwong1, YL; Kim, SJ; Tse, E; Oh, SY; Kwak, JY; Eom, HS; Do, YR; Mun, YC; Lee, SR; Shin, HJ; Suh, C; Chuang, SS; Lee, YS; Lim, ST; Izutsu, K; Suzuki, R; Relander, T; d'Amore, F; Schmitz, N; Jaccard, A; Kim, WS

CANCER RES TREAT 2018 10.4143/crt.2017.091
Validation of the Korean Version of the Quality of Life-Cancer Survivors (QOL-CS-K) Questionnaire in Lymphoma Survivors
Cho1, J; Kang, D; Kim, IR; Kim, WS; Ferrell, B; Kim, SJ

NEW ENGL J MED 2018 10.1056/NEJMoa1708984
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma
Connors1, JM; Jurczak, W; Straus, DJ; Ansell, SM; Kim, WS; Gallamini, A; Younes, A; Alekseev, S; Illes, A; Picardi, M; Lech-Maranda, E; Oki, Y; Feldman, T; Smolewski, P; Savage, KJ; Bartlett, NL; Walewski, J; Chen, R; Ramchandren, R; Zinzani, PL; Cunningham, D; Rosta, A; Josephson, NC; Song, E; Sachs, J; Liu, R; Jolin, HA; Huebner, D; Radford, J

Blood Cancer J 2017 10.1038/s41408-017-0030-y
Outcomes of patients with peripheral T-cell lymphoma in first complete remission: data from three tertiary Asian cancer centers
Tang1, T; Khoo, LP; Lim, C; Ham, JS; Kim, SJ; Hong, HM; Phipps, C; Lee, YS; Tao, M; Quek, R; Farid, M; Lin, TY; Kim, WS; Lim, ST

HEMATOL ONCOL 2017 10.1002/hon.2374
Serum level of CXCL10 is associated with inflammatory prognostic biomarkers in patients with diffuse large B-cell lymphoma
Hong1, JY; Ryu, KJ; Lee, JY; Park, C; Ko, YH; Kim, WS; Kim, SJ

HEMATOL ONCOL 2017 10.1002/hon.2374
Serum level of CXCL10 is associated with inflammatory prognostic biomarkers in patients with diffuse large B-cell lymphoma
Hong1, JY; Ryu, KJ; Lee, JY; Park, C; Ko, YH; Kim, WS; Kim, SJ

HAEMATOL-HEMATOL J 2017 10.3324/haematol.2017.169656
Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma
Younes1, A; Salles, G; Martinelli, G; Bociek, RG; Barrigon, DC; Barca, EG; Turgut, M; Gerecitano, J; Kong, O; Pisal, CB; Tavorath, R; Kim, WS

J CLIN ONCOL 2017 10.1200/JCO.2017.75.4648
Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma
Dreyling1, M; Santoro, A; Mollica, L; Leppa, S; Follows, GA; Lenz, G; Kim, WS; Nagler, A; Panayiotidis, P; Demeter, J; Ozcan, M; Kosinova, M; Bouabdallah, K; Morschhauser, F; Stevens, DA; Trevarthen, D; Giurescu, M; Cupit, L; Liu, L; Kochert, K; Seidel, H; Pena, C; Yin, SX; Hiemeyer, F; Garcia-Vargas, J; Childs, BH; Zinzani, PL

HEMATOL ONCOL 2017 10.1002/hon.2316
Pitfalls and major issues in the histologic diagnosis of peripheral T-cell lymphomas: results of the central review of 573 cases from the T-Cell Project, an international, cooperative study
Bellei1, M; Sabattini, E; Pesce, EA; Ko, YH; Kim, WS; Cabrera, ME; Martinez, V; Dlouhy, I; Paes, RP; Barrese, T; Vassallo, J; Tarantino, V; Vose, J; Weisenburger, D; Rudiger, T; Federico, M; Pileri, S

HEMATOL ONCOL 2017 10.1002/hon.2316
Pitfalls and major issues in the histologic diagnosis of peripheral T-cell lymphomas: results of the central review of 573 cases from the T-Cell Project, an international, cooperative study
Bellei1, M; Sabattini, E; Pesce, EA; Ko, YH; Kim, WS; Cabrera, ME; Martinez, V; Dlouhy, I; Paes, RP; Barrese, T; Vassallo, J; Tarantino, V; Vose, J; Weisenburger, D; Rudiger, T; Federico, M; Pileri, S

J INFECT CHEMOTHER 2017 10.1016/j.jiac.2017.04.004
Atypical presentations of MERS-CoV infection in immunocompromised hosts
Kim1, SH; Ko, JH; Park, GE; Cho, SY; Ha, YE; Kang, JM; Kim, YJ; Huh, HJ; Ki, CS; Jeong, BH; Park, J; Jang, JH; Kim, WS; Kang, CI; Chung, DR; Song, JH; Peck, KR

ONCOTARGET 2017 10.18632/oncotarget.20988
Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphoma
Hong1, J; Kim, SJ; Chang, MH; Kim, JA; Kwak, JY; Kim, JS; Yoon, DH; Lee, WS; Do, YR; Kang, HJ; Eom, HS; Park, Y; Won, JH; Mun, YC; Kim, HJ; Kwon, JH; Kong, JH; Oh, SY; Lee, S; Bae, SH; Yang, DH; Jun, HJ; Lee, HS; Yun, HJ; Lee, SI; Kim, MK; Yi, JH; Lee, JH; Kim, WS; Suh, C

J CLIN ONCOL 2017 10.1200/JCO.2017.73.3402
Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma
Vitolo1, U; Trneny, M; Belada, D; Burke, JM; Carella, AM; Chua, N; Abrisqueta, P; Demeter, J; Flinn, I; Hong, X; Kim, WS; Pinto, A; Shi, YK; Tatsumi, Y; Oestergaard, MZ; Wenger, M; Fingerle-Rowson, G; Catalani, O; Nielsen, T; Martelli, M; Sehn, LH

JPN J CLIN ONCOL 2017 10.1093/jjco/hyx120
Whole brain radiation dose reduction for primary central nervous system lymphoma patients who achieved partial response after high-dose methotrexate based chemotherapy
Park1, JS; Lim, DH; Ahn, YC; Park, W; Kim, SJ; Kim, WS; Kim, K

LEUKEMIA LYMPHOMA 2017 10.1080/10428194.2017.1298752
Report of the 6th International Workshop on PET in lymphoma
Nanni1, C; Cottereau, AS; Lopci, E; Bodet-Milin, C; Coronado, M; Pro, B; Kim, WS; Trotman, J; Barrington, S; Duhrsen, U; Vander Borght, T; Zamagni, E; Kraeber-Bodere, F; Messiou, C; Rahmouni, A; Buvat, I; Andre, M; Hertzberg, M; Oyen, W; Casasnovas, O; Luminari, S; Garderet, L; Montravers, F; Kobe, C; Kluge, R; Versari, A; Zucca, E; Moreau, P; Cheson, B; Haioun, C; Gallamini, A; Meignan, M

ANN ONCOL 2017 10.1093/annonc/mdx316
Beyond first-line non-anthracycline-based chemotherapy for extranodal NK/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease
Lim1, SH; Hong, JY; Lim, ST; Hong, H; Arnoud, J; Zhao, W; Yoon, DH; Tang, T; Cho, J; Park, S; Ko, YH; Kim, SJ; Suh, C; Lin, T; Kim, WS

HEMATOL ONCOL 2017 10.1002/hon.2283
Macrophage inflammatory protein 1 alpha (MIP-1) may be associated with poor outcome in patients with extranodal NK/T-cell lymphoma
Kim1, HS; Ryu, KJ; Ko, YH; Kim, HJ; Kim, SH; Kim, WS; Kim, SJ

ONCOTARGET 2017 10.18632/oncotarget.19301
Elevated serum interleukin-10 level and M2 macrophage infiltration are associated with poor survival in angioimmunoblastic T-cell lymphoma
Ham1, JS; Park, HY; Ryu, KJ; Ko, YH; Kim, WS; Kim, SJ

KOREAN JOURNAL OF INTERNAL MEDICINE 2017 10.3904/kjim.2015.406
Clinical features and treatment outcomes of blastic plasmacytoid dendritic cell neoplasm: a single-center experience in Korea
Kim1, HS; Kim, HJ; Kim, SH; Choi, JY; Ko, YH; Kim, WS; Jung, CW; Kim, SJ

Lancet Haematol 2017
Research on Biosimilars: pivotal trials and principles
Jurczak1, W; Vulto, AG; Amersdorffer, J; Kim, WS; Coiffier, B

Lancet Haematol 2017 10.1016/S2352-3026(17)30120-5
Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial
Kim1, WS; Buske, C; Ogura, M; Jurczak, W; Sancho, JM; Zhavrid, E; Kim, JS; Hernandez-Rivas, JA; Prokharau, A; Vasilica, M; Nagarkar, R; Osmanov, D; Kwak, LW; Lee, SJ; Lee, SY; Bae, YJ; Coiffier, B

Leuk Lymphoma. 2017 Jun;58(6):1341-1348. doi: 10.1080/10428194.2016.1236380. Epub 2016 Oct 9.
Value of interim FDG PET/CT for predicting outcome of patients with angioimmunoblastic T-cell lymphoma
Moon SH11, Lee AY1, Kim WS2, Kim SJ2, Cho YS1, Choe YS1, Kim BT1, Lee KH1.

Nutrition. 2017 Apr;36:67-71. doi: 10.1016/j.nut.2016.06.009. Epub 2016 Jun 25.
Patient-Generated Subjective Global Assessment as a prognosis tool in patients with multiple myeloma
Kim HS11, Lee JY2, Lim SH2, Cho J3, Kim SJ2, Jang JH2, Kim WS2, Jung CW2, Kim K4.

Oncotarget. 2017 Mar 28;8(13):22014-22022. doi: 10.18632/oncotarget.15782.
Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm
Yoon N11, Ahn S2, Yong Yoo H3, Jin Kim S4, Seog Kim W4, Hyeh Ko Y5.

Oncotarget. 2017 Mar 7;8(10):17038-17049. doi: 10.18632/oncotarget.14928.
The mutational landscape of ocular marginal zone lymphoma identifies frequent alterations in TNFAIP3 followed by mutations in TBL1XR1 and CREBBP
Jung H11,2, Yoo HY3, Lee SH3, Shin S4, Kim SC1, Lee S1, Joung JG1, Nam JY1,3, Ryu D1,3, Yun JW1,5, Choi JK2, Ghosh A5, Kim KK5, Kim SJ6, Kim WS6, Park WY1, Ko YH4.

J Clin Oncol. 2016 Dec 28:JCO2016690198.
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study
van Imhoff GW11, McMillan A1, Matasar MJ1, Radford J1, Ardeshna KM1, Kuliczkowski K1, Kim W1, Hong X1, Goerloev JS1, Davies A1, Barrigon MD1, Ogura M1, Leppa S1, Fennessy M1, Liao Q1, van der Holt B1, Lisby S1, Hagenbeek A1.

Oncotarget. 2017 Feb 21;8(8):13782-13791. doi: 10.18632/oncotarget.14636.
Clinical impact of serum survivin positivity and tissue expression of EBV-encoded RNA in diffuse large B-cell lymphoma patients treated with rituximab-CHOP
Hong JY11, Ryu KJ2, Park C3, Hong M4, Ko YH5, Kim WS6, Kim SJ2,6.

Oncotarget. 2017 Jan 10;8(2):2466-2476. doi: 10.18632/oncotarget.13690.
FOXO4 expression is related to stem cell-like properties and resistance to treatment in diffuse large B-cell lymphoma
Ryu KJ11, Park C2, Hong M3, Ko YH4, Kim WS5, Kim SJ1,5.

Cancer Res Treat. 2017 Jan;49(1):92-103. doi: 10.4143/crt.2015.476. Epub 2016 May 9.
Comparison of Total Body Irradiation (TBI) Conditioning with Non-TBI for Autologous Stem Cell Transplantation in Newly Diagnosed or Relapsed Mature T- and NK-Cell Non-Hodgkin Lymphoma
Maeng CH11, Ko YH2, Lim DH3, Kang ES4, Choi JY5, Kim WS6, Kim SJ6,7.

Mod Pathol. 2017 Jan;30(1):4-14. doi: 10.1038/modpathol.2016.56. Epub 2016 Sep 30.
Prognostic impact of MYC protein expression in central nervous system diffuse large B-cell lymphoma: comparison with MYC rearrangement and MYC mRNA expression
Son SM11, Ha SY1, Yoo HY2,3, Oh D4, Kim SJ3,5, Kim WS3,5, Ko YH1,3.

ONCOTARGET, JAN 17 2017, 8(3):5361-5370, DOI: 10.18632/oncotarget.14243
Epstein-Barr virus EBNA2 directs doxorubicin resistance of B cell lymphoma through CCL3 and CCL4-mediated activation of NF-kappa B and Btk
Kim JH1, Kim WS, Hong JY, Ryu KJ, Kim SJ, Park C

Oncotarget. 2016 Dec 27;7(52):86433-86445. doi: 10.18632/oncotarget.13239.
Whole-exome and transcriptome sequencing of refractory diffuse large B-cell lymphoma
Park HY11,2, Lee SB3, Yoo HY4, Kim SJ5, Kim WS5, Kim JI1, Ko YH2.

Oncotarget. 2016 Dec 20;7(51):85584-85591. doi: 10.18632/oncotarget.11319.
Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL1008)
Yoon DH11, Kim SJ2, Jeong SH3, Shin DY4, Bae SH5, Hong J6, Park SK7, Yhim HY8, Yang DH9, Lee H10, Kang HJ11, Lee MH12, Eom HS10, Kwak JY8, Lee JH6, Suh C1, Kim WS2.

Int J Hematol. 2016 Nov;104(5):591-595. Epub 2016 Jul 25.
Clinical features and treatment outcome of Epstein-Barr virus-positive nodal T-cell lymphoma
Jung KS11,2, Cho SH2, Kim SJ1, Ko YH3, Kim WS4.

Oncotarget. 2016 Nov 22;7(47):76934-76943. doi: 10.18632/oncotarget.12734.
Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era
Seo S11, Hong JY1, Yoon S1,2, Yoo C1, Park JH1, Lee JB3, Park CS4, Huh J5, Lee Y5, Kim KW6, Ryu JS7, Kim SJ8, Kim WS8, Yoon DH1, Suh C1.

Ann Oncol. 2016 Nov;27(11):2133-2134. Epub 2016 Aug 8.
Reply to the letter to the editor 'Epstein-Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin, histone deacetylase (HDAC) inhibitors when combined with a proteasome inhibitor are safe and effective in patients with extranodal natural killer/T-cell lymphoma' by Tan et al.
Kim SJ11,2, Kim WS3.

J Infect. 2016 Nov;73(5):496-505. doi: 10.1016/j.jinf.2016.06.011. Epub 2016 Jul 7.
Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients
Park S11, Kim K1, Jang JH1, Kim SJ1, Kim WS1, Chung DR2, Kang CI2, Peck KR2, Jung CW3.

Oncotarget. 2016 Nov 1;7(44):72033-72043. doi: 10.18632/oncotarget.12459.
Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study
Kim SJ11, Hong JS2, Chang MH3, Kim JA4, Kwak JY5, Kim JS6, Yoon DH7, Lee WS8, Do YR9, Kang HJ10, Eom HS11, Park Y12, Won JH13, Mun YC14, Kim HJ15, Kwon JH16, Kong JH17, Oh SY18, Lee S19, Bae SH20, Yang DH21, Jun HJ22, Kim YS23, Yun HJ24, Lee SI25, Kim MK26, Park EK27, Kim WS1, Suh C7.

Acta Haematol. 2016;136(3):186-90. doi: 10.1159/000448159. Epub 2016 Sep 14.
Mediastinal Gray Zone Lymphoma with Features Intermediate between Classical Hodgkin Lymphoma and Primary Mediastinal B-Cell Lymphoma
Song HN11, Kim SJ, Ko YH, Kim WS.

Oncotarget. 2016 Sep 13;7(37):59892-59901. doi: 10.18632/oncotarget.10988.
Blood concentration of cyclosporine during early post-transplant period may have influence on the occurrence of chronic graft versus host disease in patients who received allogeneic hematopoietic stem cell transplantation
Park S11, Kim K1, Jang JH1, Kim SJ1, Kim WS1, Jung CW1.

INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2016, 9(6):8745-8749
Multifocal lymphadenopathy due to cytomegalovirus and Epstein-Barr virus infection in lymphoma patients receiving chemotherapy: a report of two cases
Son SM1, Choi M, Kim WS, Ko YH

Bone Marrow Transplant. 2016 Jun;51(6):807-12. doi: 10.1038/bmt.2016.6. Epub 2016 Feb 8.
Prognostic relevance of pretransplant Deauville score on PET-CT and presence of EBV DNA in patients who underwent autologous stem cell transplantation for ENKTL
Lim SH11, Hyun SH2, Kim HS1, Lee JY1, Yoo KH1, Jung KS1, Song HN1, Cho J1, Park S1, Ko YH3, Kim SJ1, Choi JY2, Kim WS1.

Leuk Lymphoma. 2016;57(6):1406-12. doi: 10.3109/10428194.2015.1099650. Epub 2015 Nov 16.
A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial
Oh SY11, Kim WS2, Kim JS3, Chae YS4, Lee GW5, Eom HS6, Ryoo HM7, Lee S1, Kim SJ2, Yoon DH8, Won JH9, Hong J10, Park J10, Lee SM11, Hong JY12, Park E12, Kim HJ13, Yang DH14, Kim HJ1, Suh C8.

Haematologica. 2016 Jun;101(6):e271. doi: 10.3324/haematol.2016.148015. Epub 2016 May 31.
Author reply to Comment on: Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma, by Yoo et al.
Yoo HY11, Kim P2, Kim WS3, Lee SH1, Kim S4, Kang SY5, Jang HY6, Lee JE6, Kim J7, Kim SJ3, Ko YH8, Lee S9.

Haematologica. 2016 Jun;101(6):757-63. doi: 10.3324/haematol.2015.139253. Epub 2016 Jan 27.
Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma
Yoo HY11, Kim P2, Kim WS3, Lee SH4, Kim S5, Kang SY6, Jang HY7, Lee JE7, Kim J8, Kim SJ3, Ko YH9, Lee S10.

Leuk Lymphoma. 2016;57(6):1413-22. doi: 10.3109/10428194.2015.1113276. Epub 2015 Dec 24.
CD79B limits response of diffuse large B cell lymphoma to ibrutinib
Kim JH11, Kim WS1,2, Ryu K1, Kim SJ1,2, Park C1.

Ann Lab Med. 2016 May;36(3):209-14. doi: 10.3343/alm.2016.36.3.209.
Usefulness of Flow Cytometric Analysis for Detecting Leptomeningeal Diseases in Non-Hodgkin Lymphoma
Shin SY11,2, Lee ST2,3, Kim HJ2, Oh YL4, Kim SJ5, Kim WS5, Kim SH6.

Korean J Intern Med. 2016 May;31(3):560-9. doi: 10.3904/kjim.2014.222. Epub 2016 Feb 22.
Treatment outcomes and clinical relevance of the Follicular Lymphoma International Prognostic Index in Korean follicular lymphoma patients treated with chemotherapy
Maeng CH11,2, Ahn SW3, Ryu SY3, Han S3, Ko YH4, Ji JH5, Kim WS2, Kim SJ2.

Mod Pathol. 2016 May;29(5):430-43. doi: 10.1038/modpathol.2016.47. Epub 2016 Mar 25.
Nasal-type NK/T-cell lymphomas are more frequently T rather than NK lineage based on T-cell receptor gene, RNA, and protein studies: lineage does not predict clinical behavior
Hong M11,2, Lee T1, Young Kang S1, Kim SJ3, Kim W3, Ko YH1.

Ann Oncol. 2016 Apr;27(4):712-8. doi: 10.1093/annonc/mdv624. Epub 2016 Feb 8.
A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas
Kim SJ11, Shin DY2, Kim JS3, Yoon DH4, Lee WS5, Lee H6, Do YR7, Kang HJ2, Eom HS6, Ko YH8, Lee SH9, Yoo HY10, Hong M11, Suh C4, Kim WS12.

Clin Lymphoma Myeloma Leuk. 2016 Apr;16(4):197-202. doi: 10.1016/j.clml.2015.12.012. Epub 2016 Jan 6.
Clinical Features and Survival of Patients With Follicular Lymphoma in Korea
Cho SH11, Suh C2, Do YR3, Lee JJ4, Yun HJ5, Oh SY6, Lee HS7, Cho SG8, Cho IS9, Lee WS10, Won YW11, Kim HJ12, Lee HG13, Lee SI14, Lim SN15, Sohn BS16, Ahn HJ17, Chang MH18, Kwon KA19, Kim WS20.

J Hematol Oncol. 2016 Apr 18;9:41. doi: 10.1186/s13045-016-0271-4.
L-asparaginase-based regimens followed by allogeneic hematopoietic stem cell transplantation improve outcomes in aggressive natural killer cell leukemia
Jung KS11,2, Cho SH2, Kim SJ1, Ko YH3, Kang ES4, Kim WS5.

Cancer Chemother Pharmacol. 2016 Apr;77(4):865-73. doi: 10.1007/s00280-016-3005-y. Epub 2016 Mar 16.
Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysis
Shin DY11, Kim SJ2, Yoon DH3, Park Y4, Kong JH5, Kim JA6, Kim BS7, Kim HJ8, Won JH9, Park SK10, Kim WS11.

Lancet Oncol. 2016 Mar;17(3):389-400. doi: 10.1016/S1470-2045(15)00533-1. Epub 2016 Feb 10.
A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis
Kim SJ11, Yoon DH2, Jaccard A3, Chng WJ4, Lim ST5, Hong H6, Park Y7, Chang KM8, Maeda Y9, Ishida F10, Shin DY11, Kim JS12, Jeong SH13, Yang DH14, Jo JC15, Lee GW16, Choi CW17, Lee WS18, Chen TY19, Kim K20, Jung SH20, Murayama T21, Oki Y22, Advani R23, d'Amore F24, Schmitz N25, Suh C2, Suzuki R26, Kwong YL27, Lin TY6, Kim WS28.

Ann Oncol. 2016 Mar;27(3):508-13. doi: 10.1093/annonc/mdv596. Epub 2015 Dec 9.
Epstein-Barr virus reactivation in extranodal natural killer/T-cell lymphoma patients: a previously unrecognized serious adverse event in a pilot study with romidepsin
Kim SJ11, Kim JH2, Ki CS3, Ko YH4, Kim JS5, Kim WS6.

Oncotarget. 20